Oxford Biomedica Regulatory News (OXB)

Directorate Change

London, UK - 02 July 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces, as previously stated on 4 June 2018, Peter Nolan has retired from his role as Chief Business Officer and has stepped down from the Board.

- Ends -

Oxford BioMedica plc: Tel: +44 (0)1865 783 000

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Financial PR Enquiries: Tel: +44 (0)20 3709 5700

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal /

Oliver Manser / Laura Thornton

Peel Hunt (Joint Corporate Broker): Tel: +44 (0)20 7418 8900

James Steel / Dr. Christopher Golden

WG Partners (Joint Corporate Broker): Tel: +44 (0)20 3705 9321

David Wilson / Claes Spång

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.